Advice
in the absence of a submission from the holder of the marketing authorisation:
asfotase alfa (Strensiq®) is not recommended for use within NHSScotland.
Indication under review: Long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice619KB (PDF)
Medicine details
- Medicine name:
- asfotase alfa (Strensiq)
- SMC ID:
- SMC2433
- Indication:
Long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.
- Pharmaceutical company
- Alexion Pharma UK Ltd
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 November 2021